Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Amgen discovers kinesin-like protein KIF18A inhibitors

March 2, 2021

Bristol Myers Squibb presents new ROR-gammaT agonists

March 2, 2021

VBL Therapeutics initiates dosing patients in phase II study of VB-111 in rGBM

March 2, 2021

Oncorena cleared to begin phase I/II study in Sweden with orellanine for metastatic renal cancer

March 1, 2021

FDA grants accelerated approval to Pepaxto for relapsed or refractory melanoma

March 1, 2021

Pilot trial investigates magnetic nanoparticles to treat locally advanced pancreatic cancer

March 1, 2021

Mutant GTPase KRAS inhibitors discovered at Beijing Jacobio Pharmaceuticals

March 1, 2021

New cyclin-dependent kinase inhibitors identified at Chengdu Synowest Biotechnology

March 1, 2021

P2RX7 activator HEI-3090 shows promise for treating NSCLC

March 1, 2021

Targeting the LIGHT/LTbR pathway may be a strategy to eliminate leukemia stem cells

March 1, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...